4Davenport A. Antieoagulation options for intermittent haemodial- ysis. Minerva Urol Nefrol, 2006,58 : 171-180.
5Jarraya F, Mkawar K, Kammoun K, et al. Regional citrate antico- agulation for hemodialysis: A safe and efficient method. Saudi J Kidney Dis Transpl, 2010,21 : 533-534.
6Schneider M, Thomas K, Liefeldt L, et al. Efficacy and safety of intermittent hemodialysis using citrate as anticoagulant: A prospective study. Clin Nephrol, 2007,68: 302-307.
8Evenepoel P, Maes B, Vanwalleghem J, et al. Regional citrate an- ticoagulation for hemodialysis using a conventional calcium-containing dialysate. Am J Kidney Dis, 2002,39: 315-323.
9Kucewicz E, Zeglefl S, Wojarski J, et al. Regional citrate anticoag- ulation for continuous haemodiafiltration in the postoperative pe riod. Anestezjol Intens Ter, 2009,41 : 238-241.
10Oudemans-van Straaten HM. Citrate anticoagulation for continu- ous renal replacement therapy in the critically ill. Blood Purif, 2010,29: 191-196.
1Stangier J, Rathgen K, Stable H. Influence of renal impairment on the pharmacokinetics and pharmacodynamios of oral dabigatran etexilate: an open-label, parallel-group, single-centre study[ J ]. Clin Pharmacoki- net ,2010,49 (4) :259-268.
2Highlights of prescribing irtformation[ EB/OL]. wunv. accessdata.fda. gov/drugsatfda _ docs/label/2011/022512s0071bl, pdf , 2011-11-10/ 2014-11-20.
3Pokomey SD, Sherwood MW, Becket RC. Clinical strategies for selec- ting oral anticoagulants in patients with atrial fibrillation [ J ]. J Thromb Thrombolysis,2013 ,36( 2 ) :163-174.
4Kubitza D, Beeka M, Mueck W, et al. Effect of renal impairment on the pharmacokinetics,pharmacodynamies and safety of rivaroxaban, an oral,direct factor Xa inhibitor[J]. Br J Clin Pharmocol ,2010 , 70 ( 5 ) : 703-712.
5Highlights of prescribing information[ EB/OL]. http://www, accessda- ta. fda. gov/drugsatfda_docs/ abel/2014/022406s010lbl, pdf , 2014-02- 14/2014-10-13.
6Kubitza D,Roth A, Becka M,et al. Effect of hepatic impairment on the pharmacokineties and pharmaeodynamios of a single dose of rivaroxa- ban, an oral, direct factor Xa inhibitor [ J ]. Br J Clin Pharmacol, 2013,76( 1 ) :89-98.
7Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with at- rial fibrillation: insights from the APdSTOTLE trial[ J]. Eur Heart J, 2012,33(22) :2821-2830.
8Highlights of prescribing information[ EB/OL]. www. accessdata.fda. gov/drugsatfda _ docs/label/2012/202155s000tbl, pdf , 2012-12-31/ 2014-10-15.
9Zalpour A, Oo TH. Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence[ J ]. Drug Des Devel Ther,2014,8:2181-2191.
10Hughes GJ, Hilas O. Edoxaban : an investigational factor Xa inhibitor [J]. PT,2014,39(10) : 686-715.
